Insulet Corporation
Insulet Corporation Appoints New Auditor
Summary
On December 15, 2025, Insulet Corporation announced that its Audit Committee has appointed PricewaterhouseCoopers LLP as the Company's new independent registered public accounting firm, effective for the fiscal year ending December 31, 2026. This change follows the dismissal of Grant Thornton LLP, who previously audited the Company's financial statements for the year ending December 31, 2025. The dismissal does not affect Grant Thornton's engagement for the fiscal year ended December 31, 2025. No disagreements or reportable events were reported between the Company and Grant Thornton during their engagement period.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement